Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892329307> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2892329307 abstract "In the past few years, new drugs made their appearance in the first-line setting of treatment for metastatic renal cell carcinoma (mRCC), and cabozantinib is one among them. The present systematic review aims to point out any evidence published to date about first-line treatment with cabozantinib for mRCC patients, describing their outcome in all end points explored by the literature.PRISMA guidelines were followed. A systematic assessment of literature and peer- reviewed presentations was performed by searching PubMed and major oncology meeting resources, from the database inception until June 25, 2018. The following keywords were used: cabozantinib or cabozantinib-s-malate or XL184 and renal cell carcinoma or kidney cancer or clear cell renal carcinoma or renal cancer and first-line or untreated or treatment-naïve or primary treatment. All types of original clinical studies were included, evaluating either cabozantinib monotherapy or any systemic drug combination containing cabozantinib for previously untreated patients with mRCC.From potential 75 titles and abstracts, seven publications were selected. One was the main report of a randomized clinical trial (the CABOSUN study); four papers reported updated results, secondary or subgroup analyses from the same study population; and further two reports consisted of network meta-analyses. From the additional search for ongoing clinical trials, six studies currently in progress were reported.According to the reported evidence, cabozantinib may be a viable first-line option in mRCC patients with intermediate or poor risk according to International Metastatic Renal Cell Carcinoma Database Consortium model. It offers an undoubtful advantage in terms of progression-free survival, despite quite high rates of G3-4 toxicity, modest objective response rate, and no survival advantage. Nevertheless, given the availability of an immunotherapy combination that significantly improved overall survival for the same population in a Phase III trial and the indisputable efficacy of cabozantinib as second-line treatment, this drug may be devoted as a rescue option in patients progressive to primary therapy." @default.
- W2892329307 created "2018-09-27" @default.
- W2892329307 creator A5012176145 @default.
- W2892329307 creator A5013913173 @default.
- W2892329307 creator A5027643126 @default.
- W2892329307 date "2018-09-01" @default.
- W2892329307 modified "2023-10-14" @default.
- W2892329307 title "Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date" @default.
- W2892329307 cites W1612634664 @default.
- W2892329307 cites W1965777729 @default.
- W2892329307 cites W1986188871 @default.
- W2892329307 cites W1987977871 @default.
- W2892329307 cites W1998059407 @default.
- W2892329307 cites W2020599136 @default.
- W2892329307 cites W2079075723 @default.
- W2892329307 cites W2152294869 @default.
- W2892329307 cites W2415950182 @default.
- W2892329307 cites W2531847064 @default.
- W2892329307 cites W2558408743 @default.
- W2892329307 cites W2597355988 @default.
- W2892329307 cites W2789468111 @default.
- W2892329307 cites W2790729376 @default.
- W2892329307 cites W2792937256 @default.
- W2892329307 cites W2797935388 @default.
- W2892329307 doi "https://doi.org/10.2147/cmar.s160485" @default.
- W2892329307 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6159801" @default.
- W2892329307 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30288108" @default.
- W2892329307 hasPublicationYear "2018" @default.
- W2892329307 type Work @default.
- W2892329307 sameAs 2892329307 @default.
- W2892329307 citedByCount "3" @default.
- W2892329307 countsByYear W28923293072019 @default.
- W2892329307 countsByYear W28923293072020 @default.
- W2892329307 countsByYear W28923293072021 @default.
- W2892329307 crossrefType "journal-article" @default.
- W2892329307 hasAuthorship W2892329307A5012176145 @default.
- W2892329307 hasAuthorship W2892329307A5013913173 @default.
- W2892329307 hasAuthorship W2892329307A5027643126 @default.
- W2892329307 hasBestOaLocation W28923293071 @default.
- W2892329307 hasConcept C121608353 @default.
- W2892329307 hasConcept C126322002 @default.
- W2892329307 hasConcept C143998085 @default.
- W2892329307 hasConcept C168563851 @default.
- W2892329307 hasConcept C17744445 @default.
- W2892329307 hasConcept C189708586 @default.
- W2892329307 hasConcept C199539241 @default.
- W2892329307 hasConcept C203092338 @default.
- W2892329307 hasConcept C2777472916 @default.
- W2892329307 hasConcept C2779473830 @default.
- W2892329307 hasConcept C2781064419 @default.
- W2892329307 hasConcept C2781068499 @default.
- W2892329307 hasConcept C2908647359 @default.
- W2892329307 hasConcept C535046627 @default.
- W2892329307 hasConcept C71924100 @default.
- W2892329307 hasConcept C99454951 @default.
- W2892329307 hasConceptScore W2892329307C121608353 @default.
- W2892329307 hasConceptScore W2892329307C126322002 @default.
- W2892329307 hasConceptScore W2892329307C143998085 @default.
- W2892329307 hasConceptScore W2892329307C168563851 @default.
- W2892329307 hasConceptScore W2892329307C17744445 @default.
- W2892329307 hasConceptScore W2892329307C189708586 @default.
- W2892329307 hasConceptScore W2892329307C199539241 @default.
- W2892329307 hasConceptScore W2892329307C203092338 @default.
- W2892329307 hasConceptScore W2892329307C2777472916 @default.
- W2892329307 hasConceptScore W2892329307C2779473830 @default.
- W2892329307 hasConceptScore W2892329307C2781064419 @default.
- W2892329307 hasConceptScore W2892329307C2781068499 @default.
- W2892329307 hasConceptScore W2892329307C2908647359 @default.
- W2892329307 hasConceptScore W2892329307C535046627 @default.
- W2892329307 hasConceptScore W2892329307C71924100 @default.
- W2892329307 hasConceptScore W2892329307C99454951 @default.
- W2892329307 hasLocation W28923293071 @default.
- W2892329307 hasLocation W28923293072 @default.
- W2892329307 hasLocation W28923293073 @default.
- W2892329307 hasLocation W28923293074 @default.
- W2892329307 hasLocation W28923293075 @default.
- W2892329307 hasOpenAccess W2892329307 @default.
- W2892329307 hasPrimaryLocation W28923293071 @default.
- W2892329307 hasRelatedWork W2465616243 @default.
- W2892329307 hasRelatedWork W2785885859 @default.
- W2892329307 hasRelatedWork W2792841998 @default.
- W2892329307 hasRelatedWork W3008615512 @default.
- W2892329307 hasRelatedWork W3135168894 @default.
- W2892329307 hasRelatedWork W3216520672 @default.
- W2892329307 hasRelatedWork W4205479620 @default.
- W2892329307 hasRelatedWork W4205807138 @default.
- W2892329307 hasRelatedWork W4281645962 @default.
- W2892329307 hasRelatedWork W4285598862 @default.
- W2892329307 isParatext "false" @default.
- W2892329307 isRetracted "false" @default.
- W2892329307 magId "2892329307" @default.
- W2892329307 workType "article" @default.